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Background: The Eurocare-4 (2000–2002) period analysis docu-
ments a mean European age-adjusted 5-year relative breast can-
cer survival of 79% with higher individual figures for Finland
(85.7%), Norway (84.1%) and Sweden (86.3%) (Lancet Oncol
2007;8:784–96). The corresponding mean figure for England was
77.8%. We now compare these predicted survival estimates with
actual age-adjusted relative 5-year breast cancer overall survival
for women diagnosed with invasive breast cancer in the East of
England from 2000 to 2002.
Method: The East of England covers a population of 5.5 million
people. Five-year age-adjusted relative breast cancer survival was
calculated overall, and in specific age groups, for 10,787 women
with invasive breast cancer diagnosed from 2000 to 2002 in the
East of England for comparison with the results from the Euro-
care-4 study.
Results:
Age-adjusted 5-year relative breast cancer survival in East of
England for period 2000–2002.
Age group Number of patients Relative survival 95% CI
45–54 2563 87.5% 86.1–88.9
55–64 2945 89.5% 88.1–90.9
65–74 2335 83.9% 81.8–86.1
75+ 2944 73.3% 70.1–76.4
All women 10,787 82.5% 81.4–83.6
Conclusion: These data confirm breast cancer survival rates for
East of England that are close to European best figures for women
aged 45–64. The mean survival of 82.5% for all women however is
being reduced by worse survival in women aged 65+ and a strategy
that ensures optimal breast cancer treatment for women in this age
group should allow the mean survival to improve even further.
doi:10.1016/j.ejcsup.2010.06.053
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Background: Despite being an important health issue, breast
cancer in older women is under-researched. This study aimed
to identify how CGA may be linked to treatment decision making.
Methods: Women P70 years with newly diagnosed primary
breast cancer in Nottingham were invited to take part. Decision
for a particular treatment was made between the clinical team
and the patient, and this was not part of the study. Each patient
then completed an established CGA tool – a multi-dimensional
questionnaire incorporating information on demographics,
mood, social activities and support, medication, functional sta-
tus, cognition, nutritional state and co-morbidities.
The study is ongoing. At this preliminary analysis, 20 patients
(aged 70–87) were recruited from different treatment groups
(mastectomy n = 8, breast conserving surgery, n = 4, primary
endocrine therapy (PET) n = 7, primary radiotherapy n = 1).
Results: Compared to patients undergoing surgery, the PET
group was found to be older (median age 85 versus 76). Patients
on PET also reported having lower median physical functioning
(7.5 versus 11.5) and social support (66.67 versus 89.95) scores,
mood levels (67.65 versus 85.29) and more co-morbidities (median
4 versus 2).
Conclusions: Using a CGA tool may be beneficial in guiding
treatment decision. This ongoing study may establish a tool spe-
cific to the context of older women with primary breast cancer.
This could then become part of routine consultation and may
help identify patients who would require input of a geriatrician.
When combined with quality of life measures and biological
information, there is potential to provide a holistic approach to
this under-served population.
doi:10.1016/j.ejcsup.2010.06.054
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Introduction: Understanding the mechanisms of drug resis-
tance is important to improve and deliver effective therapy.
MicroRNAs (miRNA) are small RNA molecules that regulate gene
expression, hence we hypothesised that gene silencing, by altered
miRNA expression, causes docetaxel resistance.
Methods: Quantitative PCR-based miRNA arrays were used to
examine the role of miRNAs in acquired resistance of breast cancer
cells (MCF-7 and MDA-MB-231) to docetaxel. Quantitative PCR and
western analysis were used to measure target gene mRNA and pro-
tein expression, respectively. MicroRNA expression was modulated
and docetaxel response was measured by cell viability assay.
Results: We found 299 and 226 miRNAs altered in MCF-7 and
MDA-MB-231 docetaxel-resistant cells, respectively. Only miRNA
alterations that reached statistical significance, which targeted
experimentally validated genes involved in cell cycle, apoptosis
or drug resistance, were selected for further investigation. Doce-
taxel resistance was associated with increased expression of
miR-34a and miR-141 and decreased expression of miR-7, miR-
16, miR-30a, miR-125a-5p, miR-126 and miR-429. Computational
target prediction revealed 11 candidate genes targeted by these
miRNAs. Quantitative PCR and western analysis confirmed
decreased expression of only two genes, BCL2 and cyclinD1, in
docetaxel-resistant cells, which are both targeted by miR-34a.
Inhibition of miR-34a enhanced response to docetaxel in MCF-7
docetaxel-resistant cells whereas overexpression of miR-34a con-
ferred resistance in MCF-7 docetaxel-sensitive cells. Modulation
of miR-34a expression was correlated with expected BCL2 and
cyclinD1 protein expression changes.
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Conclusions: Our findings suggest that miR-34a is involved in
docetaxel resistance, which may act by targeting BCL2 and
cyclinD1.
doi:10.1016/j.ejcsup.2010.06.055
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Epithelial Mesenchymal Transition (EMT), as defined by loss of
epithelial characteristics and gaining a more mesenchymal-like
phenotype, has been largely reported in vivo. However, the actual
occurrence of events defining EMT is rarely fully observed in vivo.
We aimed to explore the translational landscapes of EMT in
breast cancer (BC) with relevance to potential triggering pathways
and BC molecular subtypes. Clustering analysis was performed
on a well-defined clinically annotated series of invasive non-lob-
ular BC (n = 431) prepared as tissue microarray (TMAs). A large
panel of biomarkers including cadherins, TGFb1, PIK3CA, pAkt,
cytokeratins, Erb-family members and hormone receptors, has
been studied. Differential expression of EMT markers was
observed between molecular BC subtypes (Luminal1 and 2,
HER2+, and basal-like (BLBC), where BLBC expressed lower E-
cad, higher P-cad, smooth muscle actin and PIK3CA, relative to
HER2+ BC that expressed highest levels of N-cad, TGFb1 and
PIK3CA. Within luminal tumours subdivisions, expression levels
of N-cad, TGFb1, pAkt and PIK3CA differed considerably. N-cad
contributed to cluster separation more than E-cad (F = 13.14 and
1.68, respectively). Moreover, E-cad/N-cad switch occurred more
frequently in BLBC and HER2+. Significant differences were
observed between these four clusters for breast cancer-specific
and disease-free survivals (p < 0.001).
BLBC and HER2+ BC preferentially displayed EMT/cadherin
switch than luminal BC, explaining their indigenous tendency
for progression. In addition, EMT/cadherin switch programs in
BC appear to occur synergistically with TGFb1 and PIK3/Akt path-
ways activation. These data explain, at translational level, the
varied clinical behaviour of BC molecular classes, thus could help
developing targeted therapies against EMT-associated pathways.
doi:10.1016/j.ejcsup.2010.06.056
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Cell line studies demonstrate that sphingosine kinase 1 (SK1)
and extracellular signal regulated kinase 1/2 (ERK-1/2) interact in
an oestrogen receptor (ER) dependent manner to influence
breast cancer cell growth and migration. A cohort of 304 ER posi-
tive breast cancer patients, were utilised to investigate the prog-
nostic significance of SK1, sphingosine 1-phosphate receptors 1,
2 and 3 (S1P1, S1P2 an S1P3) and ERK-1/2 expression. Expression
levels of SK1, S1P1, S1P2 and S1P3 were established by immuno-
histochemistry. Cytoplasmic and nuclear SK1 expression was
associated with shorter time to recurrence on tamoxifen (recur-
rence time) (p = 0.022 and p = 0.016, respectively) and high mem-
brane S1P1 expression was also associated with shorter time to
recurrence (p = 0.008). High cytoplasmic S1P1 and S1P3 expres-
sion were associated with shorter disease specific survival
(p = 0.036 and p = 0.019). Those patients with tumours that
expressed high levels of both cytoplasmic SK1 and ERK-1/2
had significantly shorter recurrence time than those that
expressed low levels of cytoplasmic SK1 and cytoplasmic ERK-
1/2 (p = 0.00008), with a difference in recurrence time of
10.5 years. Similarly, high cytoplasmic S1P1 and cytoplasmic
ERK-1/2 expression (p = 0.004) and high cytoplasmic S1P3 expres-
sion and cytoplasmic ERK-1/2 expression (p = 0.004), were associ-
ated with shorter recurrence time. These results support a
model in which the interaction between SK1, S1P1 and/or S1P3
and ERK-1/2 might drive breast cancer progression and this
therefore warrants further investigation.
doi:10.1016/j.ejcsup.2010.06.057
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A retrospective study was carried out comparing three cohorts
of consecutive patients diagnosed with DCIS via the NHSBSP in
the East Midlands region. Diagnostic, treatment and follow-up
outcome data was collected by individual patient case notes
review, and where necessary by contacting general practitioners.
Kaplan–Meier survival analysis was performed using SPSS.
Histological excision margins were increasingly clear over
time 88% (88/93), 91.5% (94/97) and 98% (00/03). The overall local
recurrence free survival rate was identical for both earlier periods
with 92% at 5 years but improved to 96.1% over 2000/03. 40–56% of
all local recurrences were invasive; 13/23 (88/93), 14/26 (94/97),
and 8/21 (00/03). Use of tamoxifen within the three cohorts was
similar (44–46%) and made no significant difference to rates of
local or contralateral recurrence free survival. Significant differ-
ences in local recurrence rates by operation type were observed
(see Table 1).
Conclusion: Local recurrence rates after breast conserving sur-
gery for screen detected DCIS have reduced over time. This is
likely to be related to higher rates of non-operative diagnosis,
combined with improved histological assessment (grading and
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